I want to share about the ongoing concerns regarding the ban on Ranitidine, a medication once commonly used to treat heartburn, acid reflux, and gastric ulcers. Despite its previous widespread use, the drug has been withdrawn and remains banned in most countries due to significant health concerns.

Why was Ranitidine banned?

In 2019, regulatory authorities, including the U.S. FDA, EMA, and others, discovered that Ranitidine products contained NDMA (N-nitrosodimethylamine), a probable human carcinogen. NDMA is a substance known to cause cancer in animals, and potentially in humans, especially with long-term exposure. The contamination was found to increase when Ranitidine was stored at higher temperatures or for extended periods, posing a serious health risk to patients.

Ongoing Concerns and Global Ban

Despite efforts to investigate and reformulate the drug, consistent evidence of unacceptable levels of NDMA in Ranitidine products has led to global bans and recalls.

Many health agencies continue to recommend alternative treatments, such as Proton Pump Inhibitors (PPIs) or H2-blockers like Famotidine, which do not carry the same risk.

As a precautionary measure, the bans remain in place to protect public health, while ongoing research continues to assess the long-term effects of NDMA exposure.

What Should Patients Do?

Patients who were using Ranitidine are advised to consult their healthcare provider for safer alternatives. Never stop or switch medications without proper medical advice. If you have any concerns about your past use of Ranitidine, discuss them with your doctor.

In conclusion, the withdrawal of Ranitidine underscores the importance of rigorous safety standards in pharmaceuticals. Patient safety remains our top priority, and the decision to keep Ranitidine banned in many countries is a proactive measure to prevent unnecessary health risks.

Regards,

Amit Katoch,

JAKSTAR PHARMA